Adalimumab is a fully human monoclonal antibody given by injection, used to dampen immune driven inflammation. ChEMBL records its first approval in 2002 and carries a boxed warning flag, and the WHO Anatomical Therapeutic Chemical Index classifies it as L04AB04, among the tumor necrosis factor alpha inhibitors of the immunosuppressant group. The approved indications recorded for it include psoriasis, hidradenitis suppurativa, uveitis and arthritis. The World Health Organization Model List of Essential Medicines, 24th list, from 2025, includes it in the complementary list. Several biosimilar versions have been approved since the first, among them products sold under the name Abrilada.
Facts
Classification
Approval Status ATC ClassL: Antineoplastic and Immunomodulating Agents 2 Route of Administration WHO Essential Medicine First Approved / Isolated Year Connections
Treats
Source ChEMBL, EMBL-EBI: Adalimumab approved indications (ChEMBL)
Source ChEMBL, EMBL-EBI: Adalimumab approved indications (ChEMBL)
Source ChEMBL, EMBL-EBI: Adalimumab approved indications (ChEMBL)
Source ChEMBL, EMBL-EBI: Adalimumab approved indications (ChEMBL)
Sources
1. Adalimumab (ChEMBL record)
ChEMBL molecule record, first_approval
"first_approval": 2002
ChEMBL molecule record, maximum phase and withdrawn flag
"max_phase": "4.0"
View the Source2. WHO Collaborating Centre for Drug Statistics Methodology, ATC/DDD Index: the WHO ATC/DDD Index entries named Adalimumab
WHO Collaborating Centre for Drug Statistics Methodology, ATC/DDD IndexATC/DDD Index entry; ATC class derived from cited code L04AB04 (main group L)Quote, ATC/DDD Index entry; ATC class derived from cited code L04AB04 (main group L)
L04AB04 adalimumab
3. National Library of Medicine, DailyMed: DailyMed label: HUMIRA (adalimumab) injection
National Library of Medicine, DailyMedHumira label, title sectionQuote, Humira label, title section
injection, for subcutaneous use
4. World Health Organization: The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list
World Health OrganizationPDF page 32; section 8.1; the entry adalimumab is in the Complementary List of the WHO Model List of Essential Medicines, 24th list (2025)Quote, PDF page 32; section 8.1; the entry adalimumab is in the Complementary List of the WHO Model List of Essential Medicines, 24th list (2025)
adalimumab* Therapeutic alternatives*:
ChEMBL, EMBL-EBI: Adalimumab approved indications (ChEMBL)
ChEMBL, EMBL-EBITreats: Psoriasis, drug_indication record, maximum phase 4, MeSH heading Psoriasis
"max_phase_for_ind": "4.0", "mesh_heading": "Psoriasis", "molecule_chembl_id": "CHEMBL1201580"
Treats: Hidradenitis Suppurativa, drug_indication record, maximum phase 4, MeSH heading Hidradenitis Suppurativa
"max_phase_for_ind": "4.0", "mesh_heading": "Hidradenitis Suppurativa", "molecule_chembl_id": "CHEMBL1201580"
Treats: Uveitis, drug_indication record, maximum phase 4, MeSH heading Uveitis
"max_phase_for_ind": "4.0", "mesh_heading": "Uveitis", "molecule_chembl_id": "CHEMBL1201580"
Treats: Arthritis, drug_indication record, maximum phase 4, MeSH heading Arthritis
"max_phase_for_ind": "4.0", "mesh_heading": "Arthritis", "molecule_chembl_id": "CHEMBL1201580"
View the Source Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.